Spain's Almirall Pledges $400M For Skin Drug Co. Aqua

Law360, New York (December 17, 2013, 1:10 PM EST) -- Spanish drugmaker Almirall SA said Tuesday it would pay roughly $400 million for private equity-backed prescription skin-care company Aqua Pharmaceuticals LLC, a move that will diversify its holdings and allow it to crack into the biggest dermatology market in the world.

Pennsylvania-based Aqua, majority-owned by RoundTable Healthcare Partners, manufactures treatments for acne and other skin conditions under the popular Monodox and Cordran names. The company is expected to bring in $127 million in sales for this year, fueled by its presence in its home market, a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.